机构：[1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China四川大学华西医院[2]Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Tumor Hospital, Zhengzhou, Henan 450000, China河南省肿瘤医院[3]Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing KeyLaboratory of Hematopoietic Stem Cell Transplantation, Beijing 100000, China[4]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China华中科技大学同济医学院附属同济医院[5]Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China华中科技大学同济医学院附属协和医院[6]Department of Leukemia, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences,Tianjin 300020, China[7]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510000, China[8]Department of Leukemia, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, RuijinHospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201100, China[9]Department of Hematology, Xijing Hospital, Air Force Medical University of PLA, Xi’an, Shaanxi 710000, China.
第一作者机构：[1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China
通讯作者：
通讯机构：[1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China[*1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Guoxuexiang 37, Chengdu, Sichuan 610041, China
推荐引用方式(GB/T 7714)：
Yunfan Yang,Yanli Zhang,Qian Jiang,et al.Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China.[J].CHINESE MEDICAL JOURNAL.2022,135(12):1498-1499.doi:10.1097/CM9.0000000000001899.
APA：
Yunfan Yang,Yanli Zhang,Qian Jiang,Li Meng,Weiming Li...&Huanling Zhu.(2022).Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China..CHINESE MEDICAL JOURNAL,135,(12)
MLA：
Yunfan Yang,et al."Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China.".CHINESE MEDICAL JOURNAL 135..12(2022):1498-1499
